These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Management of limited-stage Hodgkin lymphoma. Al-Juhaishi T; Ahmed S Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):500-509. PubMed ID: 38066938 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. Choi Y; Diefenbach CS Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732 [No Abstract] [Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Watkins MP; Fanale MA; Bartlett NL Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):81-90. PubMed ID: 29366607 [TBL] [Abstract][Full Text] [Related]
8. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998 [TBL] [Abstract][Full Text] [Related]
9. Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. Allen PB; Winter JN Curr Oncol Rep; 2019 Mar; 21(5):39. PubMed ID: 30919161 [TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163 [TBL] [Abstract][Full Text] [Related]
11. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704 [TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680 [TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. Castellino SM; Pei Q; Parsons SK; Hodgson D; McCarten K; Horton T; Cho S; Wu Y; Punnett A; Dave H; Henderson TO; Hoppe BS; Charpentier AM; Keller FG; Kelly KM N Engl J Med; 2022 Nov; 387(18):1649-1660. PubMed ID: 36322844 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817 [TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Abramson JS; Bengston E; Redd R; Barnes JA; Takvorian T; Sokol L; Lansigan F; Armand P; Shah B; Jacobsen E; Martignetti R; Turba E; Metzler S; Patterson V; LaCasce AS; Bello CM Blood Adv; 2023 Apr; 7(7):1130-1136. PubMed ID: 36053786 [TBL] [Abstract][Full Text] [Related]
16. Novel Therapies in the Treatment of Hodgkin Lymphoma. Andrade-Gonzalez X; Ansell SM Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826 [TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149 [TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Kumar A; Casulo C; Yahalom J; Schöder H; Barr PM; Caron P; Chiu A; Constine LS; Drullinsky P; Friedberg JW; Gerecitano JF; Hamilton A; Hamlin PA; Horwitz SM; Jacob AG; Matasar MJ; McArthur GN; McCall SJ; Moskowitz AJ; Noy A; Palomba ML; Portlock CS; Straus DJ; VanderEls N; Verwys SL; Yang J; Younes A; Zelenetz AD; Zhang Z; Moskowitz CH Blood; 2016 Sep; 128(11):1458-64. PubMed ID: 27458003 [TBL] [Abstract][Full Text] [Related]
19. Risk- and response-adapted strategies for the management of Hodgkin lymphoma. Remer M; Johnson PW Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720 [TBL] [Abstract][Full Text] [Related]
20. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. Bartlett NL Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]